News coverage about Horizon Pharma (NASDAQ:HZNP) has been trending positive on Sunday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Pharma earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.9339305028811 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Horizon Pharma (NASDAQ:HZNP) traded up $0.25 during trading on Friday, hitting $13.76. 2,013,057 shares of the company traded hands, compared to its average volume of 1,789,243. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The company has a market cap of $2,255.07, a price-to-earnings ratio of -4.51, a price-to-earnings-growth ratio of 0.64 and a beta of 1.35. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $17.69.

Several research analysts have commented on the stock. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Monday, January 8th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma in a report on Sunday, October 22nd. ValuEngine upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a report on Monday, October 16th. UBS Group set a $20.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, November 30th. Finally, BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $19.25.

ILLEGAL ACTIVITY WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Insider Buying and Selling by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with's FREE daily email newsletter.